DrugPatentWatch Database Preview
Puma Biotech Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for PUMA BIOTECH, and what generic alternatives to PUMA BIOTECH drugs are available?
PUMA BIOTECH has one approved drug.
There are nine US patents protecting PUMA BIOTECH drugs.
There are one hundred and eleven patent family members on PUMA BIOTECH drugs in twenty-seven countries.
Summary for Puma Biotech
| International Patents: | 111 |
| US Patents: | 9 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Puma Biotech
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | 8,518,446 | Start Trial | Y | Start Trial | |||
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | 9,630,946 | Start Trial | Start Trial | ||||
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | 6,288,082 | Start Trial | Y | Y | Start Trial | ||
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | 10,035,788 | Start Trial | Start Trial | ||||
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | 7,399,865 | Start Trial | Y | Y | Start Trial | ||
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | 9,211,291 | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Puma Biotech
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | 6,288,082 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Puma Biotech Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 20190128004 | Start Trial |
| South Korea | 20180041753 | Start Trial |
| Japan | 6412090 | Start Trial |
| Russian Federation | 2463300 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2005028443 | Start Trial |
| Portugal | 2498756 | Start Trial |
| Japan | 2019151671 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
